CSF and Serum sAPPα, sAPPß, NfH<sup>SMI35</sup>, and Progranulin (PRGN) in patients with ALS, Parkinson's disease (PD), and controls (CTRL).
- Petra Steinacker (120812)
- Lubin Fang (346206)
- Jens Kuhle (346208)
- Axel Petzold (120705)
- Hayrettin Tumani (120815)
- Albert C. Ludolph (108339)
- Markus Otto (120832)
- Johannes Brettschneider (158406)
Publication date
February 2013
DOIAbstract
‡<p>Comparison across all groups, Kruskal-Wallis Analysis of Variance on Ranks.</p><p>*Comparison of ALS fast vs. ALS slow, Mann-Whitney Rank Sum Test.</p><p>Fast = ALS patients with fast progression of disease over follow-up, slow = ALS patients with slow progression of disease over follow-up, S = statistical significance.</p
Add to ORKG